NOTIFICATION OF TRADE AMONG PRIMARY INSIDER

On 18 April 2012 mandatory notification of trade among primary insider Praveen Sharma of DiaGenic ASA took place. Capveen AS, which is controlled by Sharma, has sold 266,213 shares to Praveen Sharma at NOK 2.45 per share. After this transaction, Capveen AS holds no shares in DiaGenic and Praveen Sharma holds 515,290 shares in DiaGenic in addition to 16.000 share options. Sharma has increased his exposure in DiaGenic ASA by this transaction.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act).

Contact:

Henrik Lund, CEO

Telephone: 47 909 71 219

e-mail: henrik.lund@diagenic.com

Ruben Ekbråten, CFO

Telephone: 47 982 38 459

E-mail: ruben.ekbraten@diagenic.com

About DiaGenic ASA

DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic’s unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.

DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer’s disease and Parkinson’s disease. DiaGenic’s Alzheimer’s disease development program includes the CE marked diagnostic test ADtect®, for detection of mild to moderate Alzheimer’s disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer’s disease (prodromal AD).

DiaGenic’s concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com